Galectin-3: an early predictive biomarker of modulation of airway remodeling in patients with severe asthma treated with omalizumab for 36 months.
Clin Transl Allergy
; 7: 6, 2017.
Article
in En
| MEDLINE
| ID: mdl-28293414
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Type of study:
Prognostic_studies
/
Risk_factors_studies
Language:
En
Journal:
Clin Transl Allergy
Year:
2017
Document type:
Article